
Sun Pharmaceuticals has received approval from the Subject Expert Committee (SEC) under the Central Drug Standard Control Organisation (CDSCO) to produce and market Etifoxine HCl Capsule 50 mg for generalized anxiety disorder with somatic symptoms. The expert panel also recommended that the company should conduct a post-marketing surveillance (PMS) study to evaluate the drug dependence of Indian subjects.
Like
Save
Share